肝细胞癌（HCC）是一种高度侵袭性的肿瘤，具有显着的发病率和死亡率。近年来，免疫检查点抑制剂（ICIs）和激酶抑制剂的联合治疗已成为肝癌治疗的一种有前景的策略。然而，预测晚期肝癌患者联合治疗结果的临床因素仍不确定。因此，本研究调查了临床预测因素与 ICI 加激酶抑制剂治疗疗效之间的关系，以制定个性化治疗计划。我们回顾性纳入了 98 名接受 ICI 和激酶抑制剂联合治疗的晚期 HCC 患者。根据治疗前的血脂水平和其他临床因素，我们研究了可以预测该患者群体治疗反应的潜在生物标志物。该队列的平均无进展生存期 (PFS) 和总生存期 (OS) 分别为 10.1 个月和 17.2 个月，分别。通过多变量分析，无肝外转移，无门静脉血栓（PVT），中性粒细胞与淋巴细胞比值（NLR） < 3.225，血小板与淋巴细胞比值（PLR） < 140.75，预后营养指数（PNI） ) ≥ 37.25 被确定为改善 PFS 的独立预测因素。与更好的 OS 相关的因素包括 PLR < 140.75 和总胆固醇 (TC) < 3.46 mmol/L。单变量分析发现东部肿瘤合作组体能状态 (ECOG PS)、乙型肝炎病毒 (HBV) DNA 水平、Child-Pugh 分类、甲胎蛋白 (AFP)、TC 以及瑞戈非尼治疗与 PFS 之间存在显着关联。此外，ECOG PS、Child-Pugh 分类、AFP、PVT、NLR、PNI 和瑞戈非尼的接受与 OS 显着相关。PLR 和 TC 是接受 ICI/激酶的晚期 HCC 患者生存结果的潜在临床预测因素抑制剂联合治疗。在开始治疗之前了解患者的临床特征对于优化结果非常重要。© 2024。作者。

Hepatocellular carcinoma (HCC) is a highly aggressive tumor associated with significant morbidity and mortality rates. Combination therapy with immune checkpoint inhibitors (ICIs) and kinase inhibitors has emerged as a promising strategy for liver cancer treatment in recent years. However, the clinical factors predicting the outcomes of combination therapy in patients with advanced liver cancer remain uncertain. Therefore, this study investigated the relationships between clinical predictors and the efficacy of ICI plus kinase inhibitor therapy to personalize treatment plans.We retrospectively enrolled 98 patients who received combination treatment with ICIs and kinase inhibitors for advanced HCC. Based on blood lipid levels and other clinical factors prior to treatment, we investigated potential biomarkers that could predict treatment responses in this patient population.Mean progression-free survival (PFS) and overall survival (OS) in this cohort were 10.1 and 17.2 months, respectively. Via multivariate analysis, the absence of extrahepatic metastasis, the absence of portal vein thrombosis (PVT), neutrophil-to-lymphocyte ratio (NLR) < 3.225, platelet-to-lymphocyte ratio (PLR) < 140.75, and prognostic nutritional index (PNI) ≥ 37.25 were identified as independent predictors of improved PFS. Factors associated with better OS included PLR < 140.75 and total cholesterol (TC) < 3.46 mmol/L. Univariate analysis identified significant associations of Eastern Cooperative Oncology Group performance status (ECOG PS), hepatitis B virus (HBV) DNA levels, Child-Pugh classification, alpha-fetoprotein (AFP), TC, and the receipt of regorafenib with PFS. Additionally, ECOG PS, Child-Pugh classification, AFP, PVT, NLR, PNI, and the receipt of regorafenib were significantly associated with OS.PLR and TC were potential clinical predictive factors for survival outcomes in patients with advanced HCC who received ICI/kinase inhibitor combination therapy. It is important to know the clinical characteristics of patients prior to treatment initiation to optimize outcomes.© 2024. The Author(s).